Pharmaceutical - USA, Neurological

Filter

Current filters:

USANeurological

Popular Filters

1 to 25 of 70 results

NovaDel sells ZolpiMist NDA, license and IP to Amherst Pharma

23-09-2014

NovaDel Pharma has sold its insomnia drug ZolpiMist (zolpidem oral spray) New Drug Application to fellow…

Amherst PharmaceuticalsMergers & AcquisitionsNeurologicalNovaDel PharmaPharmaceuticalUSAZolpiMist

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

Biogen and AbbVie report reduced disease activity with MS drug Zinbryta

18-09-2014

US biotech company Biogen Idec and US pharma giant AbbVie have announced the full results from the Phase…

AbbVieAvonexBiogen IdecImmune systemMultiple sclerosisNeurologicalPharmaceuticalResearchUSAZinbryta

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

Depomed wins in law suit seeking FDA orphan drug exclusivity for Gralise

07-09-2014

US specialty drugmaker Depomed says that Judge Kentaji Brown Jackson of the federal district court for…

DepomedGraliseLegalNeurologicalPharmaceuticalRare diseasesUSA

Lundbeck launches Northera in USA

Lundbeck launches Northera in USA

02-09-2014

Danish CNS specialist Lundbeck said today that Northera (droxidopa) capsules for oral use are now available…

Chelsea TherapeuticsLundbeckMarkets & MarketingNeurologicalNortheraPharmaceuticalUSA

FDA backs added use for UCB’s Vimpat

01-09-2014

Belgium’s largest drugmaker UCB said today that the US Food and Drug Administration has approved a…

NeurologicalPharmaceuticalRegulationUCBUSAVimpat

ADHD treatment market set to reach $9.9 billion by 2020

ADHD treatment market set to reach $9.9 billion by 2020

22-08-2014

The attention-deficit hyperactivity disorder (ADHD) therapeutics market value will rise from $6.9 billion…

ADHDEuropeJapanNeurologicalPharmaceuticalPsychiatryUSA

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

US federal court issues restraining order against FDA's approval for generics of Hospira's Precedex

21-08-2014

A judge in US federal court has issued a temporary restraining order following the US Food & Drug Administration’s…

Food and Drug AdministrationHospiraMylanNeurologicalPharmaceuticalPrecedexUSA

Depomed prevails in Gralise ANDA litigation with Actavis

Depomed prevails in Gralise ANDA litigation with Actavis

20-08-2014

US drug maker Depomed saw its shares climb more than 12% to $14.76 on Tuesday, on the news that the firm…

ActavisDepomedGraliseLegalNeurologicalPatentsPharmaceuticalUSA

Belsomra could become first-line insomnia therapy, says GlobalData

Belsomra could become first-line insomnia therapy, says GlobalData

18-08-2014

Insomnia treatment Belsomra (suvorexant) from US pharma giant Merck & Co has the potential to become…

BelsomraChemistryCyclopyrrolonesInsomniaMarkets & MarketingMerck & CoNeurologicalOrganic chemistryPharmaceuticalUSA

Merck’s Belsomra gets FDA approval for insomnia

Merck’s Belsomra gets FDA approval for insomnia

14-08-2014

Pharma giant Merck & Co has received US Food and Drug Administration approval for its insomnia treatment…

BelsomraMerck & CoNeurologicalPharmaceuticalRegulationSedativesUSA

Teva to sue Dr Reddy’s over Copaxone patent infringement

Teva to sue Dr Reddy’s over Copaxone patent infringement

08-08-2014

Global generics leader Teva Pharmaceutical Industries yesterday confirmed that it has received the first…

CopaxoneDr Reddy's LaboratoriesLegalNeurologicalPatentsPharmaceuticalTeva Pharmaceutical IndustriesUSA

FDA performs inspection of Impax's Taiwan facility

FDA performs inspection of Impax's Taiwan facility

30-07-2014

The US Food and Drug Administration has performed a general Good Manufacturing Practices (GMP) inspection…

Impax LaboratoriesNeurologicalPharmaceuticalRegulationRytaryUSA

AcelRx Pharma’s Zalviso approval delayed by FDA

AcelRx Pharma’s Zalviso approval delayed by FDA

28-07-2014

USA-based specialty pharma firm AcelRx Pharmaceuticals says that the US Food and Drug Administration…

AcelRxFood and Drug AdministrationNeurologicalPharmaceuticalRegulationUSAZalviso

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

Biogen Idec’s Plegridy approved in Europe for relapsing-remitting multiple sclerosis

24-07-2014

US biotech firm Biogen Idec said that the European Commission has approved its subcutaneous injectable…

Biogen IdecCytokinesMultiple sclerosisNeurologicalPharmaceuticalPlegridyRegulationUSA

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Targacept trial does not show superiority of TC-1734 over donepezil

Targacept trial does not show superiority of TC-1734 over donepezil

15-07-2014

US-based clinical-stage biopharma company Targacept has announced results from a Phase IIb monotherapy…

Alzheimer's diseaseDonepezilNeurologicalPharmaceuticalResearchTargaceptTC-1734USA

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

Janssen files to expand label for Invega Sustenna to show delayed time to relapse in schizophrenia

15-07-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has submitted a supplemental…

Invega SustennaJanssenNeurologicalPharmaceuticalRegulationSchizophreniaUSA

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

15-07-2014

Swiss pharma major Novartis has set up a collaboration with US not-for-profit group the Banner Alzheimer's…

Active immunotherapyAlzheimer's diseaseEuropeNeurologicalNovartisNovartis PharmaceuticalsPharmaceuticalResearchUSA

Lundbeck and Otsuka file for US approval of brexpiprazole

Lundbeck and Otsuka file for US approval of brexpiprazole

14-07-2014

Danish CNS drug specialist Lundbeck and Japanese drugmaker Otsuka have submitted a New Drug Application…

brexpiprazoleLundbeckMarkets & MarketingNeurologicalOtsukaPharmaceuticalPiperidinesRegulationUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

1 to 25 of 70 results

Back to top